Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Ciclosporin for Treating Atopic Keratoconjunctivitis in Adults

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of Atopic Keratoconjunctivitis, a condition that causes inflammation in the eyes, often associated with allergies. The treatment being tested is called Ikervis, which is an eye drop containing the active ingredient Ciclosporin. This medication is typically used to treat severe inflammation of the cornea, the clear front part of the eye, in adults with dry eye disease. In this study, Ikervis will be used to see if it can help people with Atopic Keratoconjunctivitis.

The purpose of the study is to assess how effective Ikervis is when used four times a day for four months. Participants will be randomly assigned to receive either Ikervis or a placebo. The study will involve regular check-ups to monitor the condition of the eyes and any changes in symptoms. The main focus will be on changes in eye redness, but other aspects like eye comfort and tear production will also be evaluated.

Participants will be asked to use the eye drops daily and attend scheduled appointments for assessments. The study aims to provide valuable information on whether Ikervis can be a beneficial treatment for those suffering from Atopic Keratoconjunctivitis, potentially offering relief from the symptoms associated with this eye condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after meeting specific criteria, including being at least 18 years old and having atopic dermatitis and keratoconjunctivitis.

    The ability to attend scheduled appointments is required.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the condition of the eyes, including the presence of posterior blepharitis and signs of conjunctivitis.

    Measurements such as the Bulbar Redness score and corneal fluorescein staining are taken.

  3. Step 3

    Medication administration

    The medication Ikervis is administered as eye drops, with a concentration of 1 mg/mL.

    The drops are applied to the eyes four times daily for a duration of four months.

  4. Step 4

    Follow-up assessments

    Regular follow-up assessments are conducted to monitor changes in eye condition.

    Primary focus is on the change in the Bulbar Redness score from the start to the end of the four-month period.

  5. Step 5

    Secondary evaluations

    Additional evaluations include measuring ocular discomfort, ocular surface disease index, and tear osmolarity.

    Other assessments involve tear meniscus height, non-invasive tear break-up time, and meibography.

  6. Step 6

    Completion of the trial

    The trial concludes after the four-month treatment period.

    Final assessments are conducted to evaluate the overall effectiveness of the treatment.

Who can join the trial?

7 criteria

  • Must be at least 18 years old.
  • Have atopic dermatitis, which is a skin condition, graded as at least mild. This means:
    • An EASI-score of at least 1.1 from a dermatologist visit within the last 6 months. EASI stands for Eczema Area and Severity Index, a way to measure the severity of eczema.
    • Or a POEM-score of 3 if there were no dermatologist visits in the last 6 months. POEM stands for Patient-Oriented Eczema Measure, a questionnaire to assess eczema symptoms.
    • Have atopic keratoconjunctivitis, an eye condition, with all of the following at the time of joining:
      • At least mild posterior blepharitis or meibomian gland dysfunction. This means having at least one blocked gland in the upper eyelids.
      • Signs of conjunctivitis, which is redness in the white part of the eye, with a score of 2 or more.
      • Corneal fluorescein staining score between 1 and 4. This is a test to check for damage on the surface of the eye.
      • Must be able to attend and return for scheduled study appointments.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with Atopic Keratoconjunctivitis cannot participate. This is a condition that affects the eyes, causing inflammation and discomfort.
  • Patients who are younger than 4 years old or older than 18 years old cannot participate.
  • Patients who are part of a vulnerable population, such as those who cannot give consent or are in a dependent situation, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ikervis is an eye drop medication used in this trial to treat atopic keratoconjunctivitis, a condition that causes inflammation of the eye. The trial aims to evaluate how effective Ikervis is when used regularly over a period of four months.

What is already known about the treatment

Ikervis – Ikervis is administered as eye drops, applied directly to the eyes. It is currently being studied in clinical trials for its effectiveness in treating atopic keratoconjunctivitis, a condition characterized by inflammation of the eye's surface. The medication works by modulating the immune response, reducing inflammation at the molecular level. It is classified as an immunosuppressant, specifically targeting the eye's immune cells to alleviate symptoms.

Investigated diseases

Atopic Keratoconjunctivitis – Atopic Keratoconjunctivitis is a chronic inflammatory condition affecting the eyes, primarily seen in individuals with a history of atopic dermatitis or other allergic conditions. It involves inflammation of both the cornea and the conjunctiva, leading to symptoms such as redness, itching, and discomfort in the eyes. Over time, the condition can cause thickening of the eyelids and changes in the corneal surface, potentially affecting vision. Patients may experience increased sensitivity to light and a sensation of grittiness or burning in the eyes. The disease often follows a pattern of flare-ups and remissions, with symptoms varying in intensity.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500633-92-00Estimated enrolment40 patientsSponsorRegion Hovedstaden

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.